Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
By P. Pappas, C. Rotstein, R. Betts, M. Nucci, D. Talwar, J. D. De Waele, J. Vázquez, B. Dupont, D. Horn, L. Ostrosky-Zeichner and 7 more. Clinical Infectious Diseases, 2007
651 citations recorded by the source corpus.
Subfields: Epidemiology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/3305e2ecad2b927bf5629fab594fa5d179fe4816
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Infectious Diseases
Citations in the corpus
- Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America (2010, neutral): “This observation, coupled with the common use of fluconazole prophylaxis in the intensive care unit, suggests empiric use of echinocandins (caspofungin, anidulafungin, and micafungin) [111–115].”
- Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. (2012, neutral): “Pappas et al 2007 [49] (595; 2004–2006) Micafungin 100 or 150 mg/d for $10 d then possible switch to fluconazole 400 mg/d vs caspofungin 50 mg/d for $10 d then possible switch to fluconazole 400 mg/d Randomized, double blinded Candidemia or invasive candidiasis Hepatic dysfunction, pregnancy, cyclos”
- ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, background): “Fifteen reported primary results from clinical trials.(5-11,13-17,19,20) One publication analyzed results of a subgroup of cancer patients from a previously published trial.”
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “recipients [28] with neutropenia at onset of therapy were suc-”
- Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, methodology): “On the basis of data from recent clinical trials [28, 51, 52, 54, 79], step-down therapy to fluconazole is reasonable for patients who have improved clinically after initial therapy with an echinocandin or AmB and who are infected with an organism that is likely to be susceptible to fluconazole (e.”